Overview

Clenbuterol on Motor Function in Individuals With Amyotrophic Lateral Sclerosis

Status:
Completed
Trial end date:
2021-03-10
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and tolerability of clenbuterol (taken by mouth) in subjects with ALS (amyotrophic lateral sclerosis) and to assess the effectiveness of clenbuterol with regard to motor function in subjects with ALS. Subjects will be in this study approximately 24 weeks. The study drug, clenbuterol, is taken twice a day. As part of this study subjects will have the following tests and procedures: medical history, vital signs, physical examination, blood tests, heart and lung function tests, muscle function test, ALSFRS-R (ALS Functional Rating Scale Revised), thyroid function and for women who can become pregnant, pregnancy tests.
Phase:
Phase 2
Details
Lead Sponsor:
Dwight Koeberl, M.D., Ph.D.
Treatments:
Clenbuterol